These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Pegylated immuno-lipopolyplexes: A novel non-viral gene delivery system for liver cancer therapy.
    Author: Hu Y, Li K, Wang L, Yin S, Zhang Z, Zhang Y.
    Journal: J Control Release; 2010 May 21; 144(1):75-81. PubMed ID: 20144670.
    Abstract:
    In this study, pegylated immuno-lipopolyplexes (PILP), a novel and efficient gene delivery system was developed by employing DNA/polyethylenimine (PEI 25 kDa) polyplexes, as well as anionic liposomes composed of POPC, (DSPE)-PEG2000 and (DSPE)-PEG2000-biotin, at five different lipid/DNA molar ratios (50/1, 90/1, 130/1, 170/1 and 210/1), and by using streptavidin-monoclonal antibody conjugating through the biotin group located at the distal end of the PEG spacer as targeting antibody. This vector was highly effective in protecting DNA from enzyme digestion, and stable in particle size and zeta potential even after 20 day-storage at 4 degrees C. At the lipid/DNA molar ratio 170/1, the PILP were found to have the highest in vitro transfection efficiency with an average particle size of 132 nm and an average zeta potential of +9.5 mV. These complexes showed high efficiency in gene delivery to liver cancer cells with no significant cytotoxicity. Interestingly, the in vitro transfection efficiency did not decrease significantly up to 10 days of storage of PILP at 4 degrees C. Intravenous administration of the PILP resulted in tumor and liver targeted gene expression of the reporter genes EGFP and luciferase as opposed to the lung targeted gene expression obtained with PEI/DNA complexes, causing no cytokine production and liver injury. We conclude that the PILP are promising gene delivery systems which may be used to target the liver cancer.
    [Abstract] [Full Text] [Related] [New Search]